OraSure Technologies, Inc.

Equities

OSUR

US68554V1089

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
6.15 USD +0.16% Intraday chart for OraSure Technologies, Inc. -5.67% -25.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : OraSure Technologies, Inc., 2023 Earnings Call, Feb 27, 2024
Earnings Flash (OSUR) ORASURE TECHNOLOGIES Posts Q4 Revenue $75.9M, vs. Street Est of $74.3M MT
Earnings Flash (OSUR) ORASURE TECHNOLOGIES Reports Q4 EPS $0.22, vs. Street Est of $0.11 MT
OraSure Technologies, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023 CI
OraSure Technologies, Inc. Provides Revenue Guidance for the First Quarter 2024 CI
OraSure Technologies, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
OraSure Technologies, Inc. Seeks M&A CI
OraSure Technologies Leads Series B Funding, Strikes Distribution Rights With Sapphiros MT
Orasure Technologies, Inc. Secures Strategic Distribution Rights with Sapphiros CI
Transcript : OraSure Technologies, Inc. - Special Call
Sapphiros AI Bio LLC announced that it has received $30 million in funding from OraSure Technologies, Inc. CI
Citigroup Adjusts OraSure Technologies Price Target to $9 From $7, Maintains Buy Rating MT
Tranche Update on OraSure Technologies, Inc.'s Equity Buyback Plan announced on August 5, 2008. CI
OraSure Technologies to Seek Acquisitions CI
Transcript : OraSure Technologies, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Earnings Flash (OSUR) ORASURE TECHNOLOGIES Posts Q3 Revenue $89.2M, vs. Street Est of $74.6M MT
Earnings Flash (OSUR) ORASURE TECHNOLOGIES Reports Q3 EPS $0.27, vs. Street Est of $0.08 MT
OraSure Technologies, Inc. Provides Financial Guidance for the Fourth Quarter 2023 CI
OraSure Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Evercore ISI Adjusts OraSure Technologies Price Target to $6.50 From $5, Maintains In Line Rating MT
Tranche Update on OraSure Technologies, Inc.'s Equity Buyback Plan announced on August 5, 2008. CI
Transcript : OraSure Technologies, Inc., Q2 2023 Earnings Call, Aug 03, 2023
Earnings Flash (OSUR) ORASURE TECHNOLOGIES Reports Q2 Revenue $85.4M, vs. Street Est of $63.9M MT
Earnings Flash (OSUR) ORASURE TECHNOLOGIES Reports Q2 EPS $0.09 MT
OraSure Technologies, Inc. Provides Revenue Guidance for the Third Quarter of 2023 CI
Chart OraSure Technologies, Inc.
More charts
OraSure Technologies, Inc. provides point-of-care and home diagnostic tests, sample management solutions, and microbiome laboratory and analytical services. The Company's product portfolio is divided into diagnostics products and sample management solutions. Its business consists of the development, manufacture, marketing and sale of diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its diagnostic products include tests for diseases including COVID-19, HIV and Hepatitis C that are performed on a rapid basis at the point of care, and tests for drugs of abuse that are processed in a laboratory. Its business also includes molecular sample management solutions and services that are used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
6.15 USD
Average target price
7.65 USD
Spread / Average Target
+24.39%
Consensus
  1. Stock
  2. Equities
  3. Stock OraSure Technologies, Inc. - Nasdaq
  4. News OraSure Technologies, Inc.
  5. Insider Trends: OraSure Technologies Insider Gets Stock Award Makes Tax Sale with Portion, Interrupting 90-Day Buy Trend